SecBot SecBot
SECBOTREPLAY Home › Report › URGN

URGN · UroGen Pharma settled patent litigation with Teva over Jelmyto…

UroGen Pharma Ltd. · 8-K filed Jun 2, 2026 at 08:04 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Jun 2, 2026 at 08:04 ET

UroGen Pharma settled patent litigation with Teva over Jelmyto (mitomycin) for pyelocalyceal solution. Under the settlement, UroGen grants Teva a non-exclusive license to sell a generic version beginning September 15, 2030, if FDA-approved. The agreement resolves all ongoing patent litigation in the U.S. District Court for the District of Delaware and is subject to FTC/DOJ review.

  • UroGen entered a settlement and license agreement with Teva resolving patent litigation over Jelmyto (mitomycin) for pyelocalyceal solution.
  • Teva will receive a non-exclusive license to sell its generic version of Jelmyto beginning September 15, 2030, if FDA-approved.
  • All ongoing patent litigation between the parties in the U.S. District Court for the District of Delaware will be terminated.
  • The agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access